A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.

Market Analysis and Insights: Global Propylthiouracil (PTU) Market
In 2020, the global Propylthiouracil (PTU) market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Propylthiouracil (PTU) Scope and Market Size
The global Propylthiouracil (PTU) market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Propylthiouracil (PTU) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
Finished Drug Product
Active Pharmaceutical Ingredients

Segment by Application
Radioiodine Therapy
Hyperthyroidism Operation
Thyroid Medication
Other

By Company
Actavis (TEVA )
Par Pharmaceutical (Endo International)
Apotex Corporation
Cardinal Health
Pharmascience (Joddes)
Hikma
Dr. Herbrand KG
Shanghai Pharmaceuticals
Shanghai Zhaohui Pharmaceutical
Guangdong South China Pharmaceutical Group
Guangzhou Kanghe Pharmaceutical
Jinghua Pharmaceutical Group
Suzhou Dongrui Pharmaceutical

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE